Brilinta DaYu Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2004 participants.

Also called NCT01870921

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,004 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01870921
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01870921. Allocation not applicable; no masking; primary purpose treatment. Start 2013-06-26 (actual); primary completion 2015-09-30 (actual). Results posted on 2016-11-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Brilinta DaYu Study
Acronym
DaYu
Condition
Acute Coronary Syndrome
Intervention (Drug)
Ticagrelor
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct01870921
Content hash
c0eacab8a8eeb3994a537faa89b5f8b7c9d22fab280b06fd4087268e1d88eba1